
    
      Primary Objective:

      Determine the safety of Tumor Treating Fields (TTFields) started concurrently with 5 fraction
      stereotactic radiosurgery (SRS) and temozolomide for newly diagnosed glioblastoma. secondary
      objective: Efficacy for the combination of TTFields started concurrently with 5
    
  